Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...
DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating yesterday. Nico Chen has given his Buy rating due ...
With valuations growing across the stock market and the biopharma sector, it's only natural for value-sensitive investors to ...
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...
Eli Lilly and Co. (LLY) is planning to invest $364 million or 279 million pounds in the biotechnology segment in the U.K., to ...
One of the downsides of treatments such as Ozempic or Mounjaro is that even though patients wind up losing weight, they also tend to shed muscle mass. Losing too much muscle mass can be a health risk ...
The drugmaker Eli Lilly told the-then UK health secretary last year that its new Alzheimer’s drug could be a one-off ...
Danish biotech Zealand Pharma is targeting the "next generation" of weight loss drugs as competitors pile into a market ...